Jiangsu Yanshen Biological Technology Stock Co. was given a new drug certificate and production license from the SFDA for the company’s H1N1 flu vaccine. The action brings the number of approved manufacturers of H1N1 vaccines in China to six. Simcere Pharmaceutical Company (先声药业) owns a 37.5% stake in Jiangsu Yanshen, which it bought in May of this year for 195.5 million RMB ($28.8 million). More details...

Stock Symbol: (NYSE: SCR)